Drug updated on 9/14/2023
|Injection (intravenous; 100 mg or 500 mg)
|Folate analog metabolic inhibitor
| Ongoing and
- Indicated in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
- Indicated in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.
- Indicated as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
- Indicated as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.
Product Monograph / Prescribing Information
|Alimita (pemetrexed) Prescribing Information.
|Lilly USA, LLC Indianapolis, IN
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
|Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology.
|Journal of the National Comprehensive Cancer Network
|SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).
|Clinical and Translational Oncology